Five-year follow-up of a single centre uro-oncology tumour board decisions

The quality of the oncologic care is evaluable with meaningful outcome indicators. Five-year overall survival (OS) rate is a good indicator for treatments of curative intent for localised diseases. One-year OS rate and median survival are good indictors for treatments of palliative intent for metastatic diseases. This study assessed 5-year follow-up data of a regional uro-oncological centre. Patients presented at the multidisciplinary uro-oncology tumour board of Petz Aladár Hospital are prospectively followed-up. In 2017 the oncology board made decisions for the treatment of 353 patients. No patient diagnosed with urological malignancy was excluded. Patients were offered validated surgical, radiation or medical treatments of curative or palliative intent consistent with international guidelines or comfort treatment if anticancer therapy was not possible. The 5-year disease specific OS rate of patients treated for localised prostate-, kidney- and muscle invasive bladder cancer was 79%, 81% and 21% respectively. The respective 1-year OS rate of patients treated for metastatic prostate-, kidney- and bladder cancer was 70%, 40% and 33%, median survival was 36, 8 and 8 months. This simple method of surveillance is suitable for the internal quality control of a multidisciplinary tumour board. The data of the first 5-year follow-up indicate well balanced care for urological malignancies at Petz Aladár Hospital. The results correspond to high quality requirements in a country with generally poor oncologic outcome indicators.